NovoCure (NVCRN) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVCRN Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

NovoCure

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVCRN Stock 12 Month Forecast

Average Price Target

$468.48

▲(77.45% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $468.48 with a high forecast of $902.26 and a low forecast of $294.97. The average price target represents a 77.45% change from the last price of $264.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"206":"$206","903":"$903","380.25":"$380.3","554.5":"$554.5","728.75":"$728.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":902.26085768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$902.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":468.48159918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$468.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":294.96989578,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$294.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[206,380.25,554.5,728.75,903],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,264.01,313.10621982153845,362.2024396430769,411.2986594646154,460.3948792861538,509.4910991076923,558.5873189292308,607.6835387507692,656.7797585723076,705.8759783938461,754.9721982153847,804.068418036923,853.1646378584616,{"y":902.26085768,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,264.01,279.73858455230766,295.4671691046154,311.19575365692305,326.92433820923077,342.65292276153843,358.38150731384616,374.1100918661538,389.83867641846155,405.5672609707692,421.2958455230769,437.0244300753846,452.7530146276923,{"y":468.48159918,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,264.01,266.3915304446154,268.77306088923075,271.15459133384616,273.5361217784615,275.9176522230769,278.2991826676923,280.68071311230767,283.0622435569231,285.4437740015385,287.82530444615384,290.20683489076924,292.5883653353846,{"y":294.96989578,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":303.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$902.26

Average Price Target$468.48

Lowest Price Target$294.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Nierengarten

Wedbush

$312.32→$347.02

Hold

31.44%

Upside

Reiterated

07/24/26

Novocure price target raised to $20 from $18 at WedbushNovocure price target raised to $20 from $18 at Wedbush

Emily Bodnar

H.C. Wainwright

$902.26

Buy

241.75%

Upside

Assigned

07/24/26

Novocure price target raised to $52 from $46 at H.C. WainwrightNovocure price target raised to $52 from $46 at H.C. Wainwright

Jason Bednar

Piper Sandler

$503.18

Buy

90.59%

Upside

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Jessica Fye

J.P. Morgan

$294.97

Hold

11.73%

Upside

Reiterated

07/13/26

J.P. Morgan Sticks to Its Hold Rating for NovoCure (NVCR)

Larry Biegelsen

Wells Fargo

$234.24→$294.97

Hold

11.73%

Upside

Assigned

05/04/26

Novocure price target raised to $17 from $13.50 at Wells FargoNovocure price target raised to $17 from $13.50 at Wells Fargo

Vijay Kumar

Evercore ISI

$277.62→$347.02

Buy

31.44%

Upside

Reiterated

05/01/26

Novocure price target raised to $20 from $16 at Evercore ISINovocure price target raised to $20 from $16 at Evercore ISI

Unknown Analyst

Ladenburg Thalmann & Co.

Not Ranked

Ladenburg Thalmann & Co.

$468.48

Buy

77.45%

Upside

Reiterated

02/27/26

Ladenburg Thalmann & Co. Remains a Buy on NovoCure (NVCR)

Jonathan Chang

Leerink Partners

$416.43

Buy

57.73%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Henry Schein (NASDAQ: HSIC) and NovoCure (NASDAQ: NVCR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Nierengarten

Wedbush

$312.32→$347.02

Hold

31.44%

Upside

Reiterated

07/24/26

Novocure price target raised to $20 from $18 at WedbushNovocure price target raised to $20 from $18 at Wedbush

Emily Bodnar

H.C. Wainwright

$902.26

Buy

241.75%

Upside

Assigned

07/24/26

Novocure price target raised to $52 from $46 at H.C. WainwrightNovocure price target raised to $52 from $46 at H.C. Wainwright

Jason Bednar

Piper Sandler

$503.18

Buy

90.59%

Upside

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Jessica Fye

J.P. Morgan

$294.97

Hold

11.73%

Upside

Reiterated

07/13/26

J.P. Morgan Sticks to Its Hold Rating for NovoCure (NVCR)

Larry Biegelsen

Wells Fargo

$234.24→$294.97

Hold

11.73%

Upside

Assigned

05/04/26

Novocure price target raised to $17 from $13.50 at Wells FargoNovocure price target raised to $17 from $13.50 at Wells Fargo

Vijay Kumar

Evercore ISI

$277.62→$347.02

Buy

31.44%

Upside

Reiterated

05/01/26

Novocure price target raised to $20 from $16 at Evercore ISINovocure price target raised to $20 from $16 at Evercore ISI

Unknown Analyst

Ladenburg Thalmann & Co.

Not Ranked

Ladenburg Thalmann & Co.

$468.48

Buy

77.45%

Upside

Reiterated

02/27/26

Ladenburg Thalmann & Co. Remains a Buy on NovoCure (NVCR)

Jonathan Chang

Leerink Partners

$416.43

Buy

57.73%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Henry Schein (NASDAQ: HSIC) and NovoCure (NASDAQ: NVCR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NovoCure

3 Months

Jason BednarPiper Sandler

Success Rate

17/31 ratings generated profit

Average Return

+7.31%

Copying Jason Bednar's trades and holding each position for 3 Months would result in 54.84% of your transactions generating a profit, with an average return of +7.31% per trade.

1 Year

Jason BednarPiper Sandler

Success Rate

12/31 ratings generated profit

Average Return

+5.25%

Copying Jason Bednar's trades and holding each position for 1 Year would result in 38.71% of your transactions generating a profit, with an average return of +5.25% per trade.

2 Years

Emily BodnarH.C. Wainwright

Success Rate

8/23 ratings generated profit

Average Return

-14.59%

Copying Emily Bodnar's trades and holding each position for 2 Years would result in 34.78% of your transactions generating a profit, with an average return of -14.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVCRN Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVCRN has received 5 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NVCRN average Analyst price target in the past 3 months is 468.48.

Each month's total comprises the sum of three months' worth of ratings.

NVCRN Financial Forecast

NVCRN Earnings Forecast

Next quarter’s earnings estimate for NVCRN is -$4.27 with a range of -$5.58 to -$2.44. The previous quarter’s EPS was -$2.27. NVCRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 43.75% of the time in the same period. In the last calendar year NVCRN has Performed in-line its overall industry.

NVCRN Sales Forecast

Next quarter’s sales forecast for NVCRN is $3.18B with a range of $3.13B to $3.27B. The previous quarter’s sales results were $3.20B. NVCRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 55.56% of the time in the same period. In the last calendar year NVCRN has Performed in-line its overall industry.

NVCRN Stock Forecast FAQ

What is MX:NVCRN’s average 12-month price target, according to analysts?

Based on analyst ratings, NovoCure Ltd’s 12-month average price target is 468.48.

What is MX:NVCRN’s upside potential, based on the analysts’ average price target?

NovoCure Ltd has 77.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NovoCure Ltd a Buy, Sell or Hold?

NovoCure Ltd has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is NovoCure Ltd’s share price target?

The average share price target for NovoCure Ltd is 468.48. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $902.26 ,and the lowest forecast is $294.97. The average share price target represents 77.45% Increase from the current price of $264.01.

What do analysts say about NovoCure Ltd?

NovoCure Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of NovoCure Ltd?

To buy shares of MX:NVCRN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

NovoCure (NVCRN) Stock Forecast & Price Target

NVCRN Analyst Ratings

NVCRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NovoCure

NVCRN Analyst Recommendation Trends

NVCRN Financial Forecast

NVCRN Earnings Forecast

NVCRN Sales Forecast

NVCRN Stock Forecast FAQ

Detailed List of Analyst Forecasts